|
|
|
|
|
|
|
|
|
|
|
|
|
|
13.05.25 - 13:06
|
Atlantic Union Bankshares Announces Appointment of Bradley S. Haun as Chief Risk Officer (Business Wire)
|
|
RICHMOND, Va.--(BUSINESS WIRE)--Atlantic Union Bankshares Corporation (“Atlantic Union”) announced the appointment of Bradley S. Haun as chief risk officer of Atlantic Union and Atlantic Union Bank. Mr. Haun succeeds Sherry Williams, who will retire on July 1, 2025. Ms. Williams is currently serving in an advisory capacity until her retirement date.
Mr. Haun has been with Atlantic Union since 2011, most recently serving as executive vice president and chief audit executive. Mr. Haun, an alumnus of Virginia Tech, began his career at Cherry Bekaert in their audit practice. He joined Atlantic Union as director of financial reporting and accounting policy before becoming corporate controller. He was named chief audit executive in 2021.
“It has been an honor to work with Sherry, who has been instrumental in building out our enterprise risk program to support the increased regulatory expectations associated with our growing company,” said Chief Executive Officer John Asbury. “We thank her for her many...
|
|
12.05.25 - 17:27
|
Orca Bio Announces Leadership Updates (Business Wire)
|
|
Co-founder and Chief Scientific Officer of Orca Bio, Nate Fernhoff, Ph.D., appointed Chief Executive Officer
Co-founder and Chief Operating Officer of Orca Bio, Jeroen Bekaert, Ph.D., appointed President
Company is accelerating investment in manufacturing and commercial infrastructure in preparation for planned 2025 BLA to the U.S. FDA
MENLO PARK, Calif.--(BUSINESS WIRE)--Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced the appointment of the company's co-founder and Chief Scientific Officer, Nate Fernhoff, Ph.D., as Chief Executive Officer (CEO), succeeding Ivan Dimov, Ph.D. In addition, co-founder and Chief Operating Officer, Jeroen Bekaert, Ph.D., has assumed the role of President.
“I am honored and humbled to serve as CEO as we progress toward our vision of transforming the treatment landscape for patients living with blood cancer,” said Dr. Fernhoff. “Following the positive Phase 3 results for Orca...
|
|
|
|
|
|
|